share_log
Breakings ·  01:58

July 2 (Reuters) - Eli Lilly and Co Lly.n:

  • Lilly's Kisunla™ (Donanemab-Azbt) Approved by the FDA for the Treatment of Early Symptomatic Alzheimer's Disease

  • Eli Lilly: Price of Each Vial of Kisunla Is $695.65

  • Eli Lilly: Coverage & Reimbursement for Kisunla Now Available for Eligible Patients on Medicare

  • Eli Lilly: Kisunla 6 Months Length of Treatment With 6 30-Minute Infusions to Cost $12,522

  • Eli Lilly - Kisunla 12 Months Length of Treatment With 13 30-Minute Infusions to Cost $32,000

  • Eli Lilly: Intends to Donate Kisunla to Lilly Cares Foundation

Source Text for Eikon: Id:Npn5Yfd56a

Further Company Coverage: Lly.n


((Reuters.briefs@Thomsonreuters.com;))

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment